cash equivalents increased by Baht 10. 60 million due to better liquidity of the group as a result from Initial Public Offering (IPO). • Restricted cash decreased by Baht 51. 06 million because repayment

Mai amount Baht 30.48 million, invest in the second branch of Hemodialysis center amount Baht 7.30 million and payment for purchase assets in the 3rd branch of dialysis unit at 10.00 MB, repayment for

% decreased from year ended 2016. This was a consequence of: 1. Long-term loan from other parties increased by THB 1,479 million in 2017 for repayment the liabilities under debt restructuring regarding to the

. Long-term loan from other parties increased by THB 1,479 million in 2017 for repayment the liabilities under debt restructuring regarding to the major 4 trade creditors. 2. Debt restructuring according

(i.e. annual report, AGM arrangement), etc. 4. Finance cost For 2Q17, finance cost was decreased to Baht 0.03 million, decreased by 99.33% YoY as a result of fully repayment of all bank loan in late 2016

99.34% YoY as a result of fully repayment of all bank loan in late 2016. 5. Net profit and net profit margin The 3Q17 net profit was Baht 17.39 million, representing the net profit margins of 6.55% and

value of transaction comprises of loans value equivalent to maximum Baht 94 million and the total cost of financing of Baht 5.875 million for the period of 6 months ending September 30, 2017. Thus, total

largely been completed. Income tax expense has decreased due to the lower EBITDA. Net income was up 5% due to a decrease in financing costs as interest rates have reduced which is positive and the lower tax

from THB 24.6 Mn to THB 3.7 Mn respectively, a decrease of THB 20.9 Mn or 85.0%. This was due to the repayment of loans from commercial banks following the initial public offering. Tax Expenses For the

from financing activities 0% Receive from non-controling interests from increase capital of subsidiary 1,429,158 - 100% Finance costs paid (340,581) (404,654) -19% Repayment of liabilities from